- Advanced Fellowship - Vanderbilt University Medical Center (1999-2000), Bone Marrow Transplant
- Fellowship - University of Pittsburgh (1996-1999), Hematology Oncology
- Internship - Delhi University/Maulana Azad Medical College, India (1992-1993), Internal Medicine
- Medical School - Lady Hardinge Medical College, India (1986-1991)
- Residency - SUNY Upstate Medical University (1993-1996), Internal Medicine
Madhuri Vusirikala, M.D.
- Internal Medicine - Hematology/Oncology
- Lymphoma Treatment
- Malignant Hematology
Madhuri Vusirikala, M.D., is a Professor of Internal Medicine in the Division of Hematology/Oncology at UT Southwestern Medical Center. She joined UT Southwestern in 2006.
Dr. Vusirikala specializes in managing a variety of hematologic malignancies and, when appropriate, performing bone marrow transplants to treat them.
As Medical Director of UT Southwestern’s Adult Bone Marrow Transplant Program, Dr. Vusirikala works with the National Marrow Donor Program. She also leads the Bone Marrow Transplant and Hematologic Malignancies Clinic’s Chronic Graft-Versus-Host Disease Clinic and serves as a staff physician on the Hematology-Oncology/Bone Marrow Transplant Service of UT Southwestern’s Zale Lipshy University Hospital and William P. Clements Jr. University Hospital.
Dr. Vusirikala earned her medical degree (M.B.B.S.) at India’s Lady Hardinge Medical College before completing an internal medicine internship at Maulana Azad Medical College-Delhi University and an internal medicine internship and residency at The State University of New York, Syracuse.
She also completed a hematology and oncology fellowship at the University of Pittsburgh and an advanced fellowship in bone marrow transplantation at Vanderbilt University Medical Center.
Dr. Vusirikala serves as the primary investigator for most of UT Southwestern’s clinical trials related to bone marrow transplantation. Her research interests include chronic graft-versus-host disease, allogeneic stem cell transplantation, hematopoietic and cord-blood transplantation, chronic lymphocytic leukemia, and peripheral T-cell lymphoma.
She is board certified in internal medicine, oncology, and hematology. A member of the UT Southwestern Protocol Review and Monitoring Committee, she also is involved with groups that include the Laboratory Advisory Committee and with teams aimed at bone marrow transplant implementation and chemotherapy safety.
Dr. Vusirikala is a member of the American Society of Hematology, American Society of Clinical Oncology, American Society of Bone Marrow Transplant, and American College of Physicians.
Meet Dr. Vusirikala
Bone Marrow Transplant Specialist
Patients with hematologic malignancies who may require bone marrow transplantation are in good hands with UT Southwestern Medical Center's Madhuri Vusirikala, M.D.
Dr. Vusirikala takes care of adults with blood cancers and offers bone marrow transplants for any diseases that require them. She performs a variety of transplants, including autologous, allogeneic, cord blood, and haploidentical. She also treats patients who don’t require transplantation but whose conditions require highly skilled maintenance care, including a number of patients transplanted at other centers.
“We get many referrals, both for transplanting patients and for treating patients with complex and chronic hematologic diseases,” she says.
Dr. Vusirikala runs the Bone Marrow Transplant and Hematologic Malignancies Clinic’s Chronic Graft-Versus-Host Disease (GVHD) Clinic, a survivorship program that serves patients who develop this complication after an allogeneic transplantation. She is also the Director of the National Marrow Donor Program portion of the UT Southwestern stem cell transplant program.
As the primary investigator of most of UT Southwestern’s clinical trials related to bone marrow transplantation, Dr. Vusirikala is active in clinical research and says she takes pride in being thorough and looking at the big picture for each patient.
“I try to be a very comprehensive transplant physician, one who considers each patient as an individual and takes an aggressive yet sensitive approach,” she says. “I weigh the risks of transplantation with the benefits – in the short term and the long term. Sometimes, transplant is not the best treatment for a patient, and I believe in reviewing all treatment options available and helping pick the best treatment for that patient.”
Dr. Vusirikala thinks it's important to educate both the patient and his or her family and build a strong relationship with every patient. There is so much information out there for patients and sometimes it gets very confusing as to what is beneficial, she says. Dr. Vusirikala believes in reviewing all the information with patients and their families and helping them interpret the data.
“Patients should always look at transplant center statistics, ask questions, and talk with other patients who have been treated at that center,” she says. “Patients should feel like they can approach their transplant physician with any issue at any time and have all their questions and concerns addressed. I’m a strong believer in that.”
- American Society of Hematology (1998), Member
- American Society of Bone Marrow Transplant (2010), Member
Supportive Care in Hematologic Malignancies in Wintrobe's Clinical Hematology, 11th edition.
Vusirikala, Madhuri (2003), Philadelphia, Lippincott Williams & Wilkins
Supportive Care in Hematologic Malignancies in Wintrobe's Clinical Hematology, 12th edition.
Vusirikala, Madhuri (2009), Philadelphia, Lippincott Williams & Wilkins
- Supportive Care in Hematologic Malignancies in Wintrobe's Clinical Hematology, 11th edition.
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Soiffer RJ, Kim HT, McGuirk J, Horwitz ME, Johnston L, Patnaik MM, Rybka W, Artz A, Porter DL, Shea TC, Boyer MW, Maziarz RT, Shaughnessy PJ, Gergis U, Safah H, Reshef R, DiPersio JF, Stiff PJ, Vusirikala M, Szer J, Holter J, Levine JD, Martin PJ, Pidala JA, Lewis ID, Ho VT, Alyea EP, Ritz J, Glavin F, Westervelt P, Jagasia MH, Chen YB Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Oct JCO2017758177
Novel Application of Extracorporeal Photopheresis as Treatment of Graft-versus-Host Disease Following Liver Transplantation.
Brown TJ, Gentry C, Hammer ST, Hwang CS, Vusirikala M, Patel PA, Matevosyan K, Tujios SR, Mufti AR, Collins RH ACG case reports journal 2017 4 e48
Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia, results from two clinical trials.
Schlenk R, Krauter J, Raffoux E, Kreuzer KA, Schaich M, Noens L, Pabst T, Vusirikala M, Bouscary D, Spencer A, Candoni A, Sierra Gil J, Berkowitz N, Weber HJ, Ottmann O Haematologica 2017 Oct
PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab.
Salahudeen AA, Gupta A, Jones JC, Cowan RW, Vusirikala M, Kwong C, Naina HV Clinical lymphoma, myeloma & leukemia 2015 Jun
Hematogone hyperplasia in copper deficiency.
Sutton L, Vusirikala M, Chen W American journal of clinical pathology 2009 Aug 132 2 191-9; quiz 307
A phase II trial of high dose chemotherapy and conccurrent rituximab followed by autologous peripheral blood stem cell transplantation for treatment of relapsed CD20 positive B-cell Non-Hodgkin’s Lymphoma
Vusirikala M, Stein RS, Brandt S, Morgan D, Greer J, Jagasia M, Kassim A, Schuening F, Goodman S Biol Blood Marrow Transplant 2002 8 101
Dose-Intensification and Stem Cell Transplantation (SCT) for histologically transformed Low-grade Follicular Non-Hodgkin Lymphoma (NHL): A single center experience
Vusirikala M, Brandt S, Chinratanalab W, Greer JP, Jagasia M, Kassim A, Mineshi S, Morgan DS, Ruffner K, Friedrich SG, Shyr Y, Goodman SA Biol Blood Marrow Transplant 2004 10 192
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Naina HV, Levitt D, Vusirikala M, Anderson LD, Scaglioni PP, Kirk A, Collins RH Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Jun 29 18 e534-6
Valacyclovir for the prevention of cytometalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA Bone Marrow Transplant August 2001 28 265-70
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
- survivorship after stem cell transplant
- Other malignant hematologic disorders-lymphomas, MDS, MPD, MF, myeloma
- acute leukemias
- acute and chronic graft versus host disease
- allogeneic stem cell transplant in hematologic disorders
- Lymphoma Treatment
- Malignant Hematology
- Bone Marrow Transplant
- Leukemia Treatment
- Myeloma Treatment
Q&A by Dr. Vusirikala
Showing 1 locations